Journal
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Volume 21, Issue 3, Pages 403-413Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737167.2021.1917385
Keywords
Micro-costing; whole genome sequencing; standard diagnostic techniques; oncology; personalized medicine
Funding
- Netherlands Organisation for Health Research and Development [ZonMw] [846001001, 846001002]
- HMF
- Dutch Cancer Society (KWF Kankerbestrijding)
- Dutch health-care insurance company Zilveren Kruis
Ask authors/readers for more resources
This study calculated and compared the total cost of current diagnostic techniques and WGS in the treatment of NSCLC, melanoma, CRC, and GIST in the Netherlands. The results showed that operational costs accounted for over 90% of the total cost per technique, with variations ranging from euro 58 to euro 2925 per cancer patient. Detailed cost differences and value comparisons between these diagnostic techniques enable future economic evaluations to support decision-making.
Purpose: Predictive diagnostics play an increasingly important role in personalized medicine for cancer treatment. Whole-genome sequencing (WGS)-based treatment selection is expected to rapidly increase worldwide. This study aimed to calculate and compare the total cost of currently used diagnostic techniques and of WGS in treatment of non-small cell lung carcinoma (NSCLC), melanoma, colorectal cancer (CRC), and gastrointestinal stromal tumor (GIST) in the Netherlands. Methods: The activity-based costing (ABC) method was conducted to calculate total cost of included diagnostic techniques based on data provided by Dutch pathology laboratories and the Dutch-centralized cancer WGS facility. Costs were allocated to four categories: capital costs, maintenance costs, software costs, and operational costs. Results: The total cost per cancer patient per technique varied from euro 58 (Sanger sequencing, three amplicons) to euro 2925 (paired tumor-normal WGS). The operational costs accounted for the vast majority (over 90%) of the total per cancer patient technique costs. Conclusion: This study outlined in detail all costing aspects and cost prices of current and new diagnostic modalities used in treatment of NSCLC, melanoma, CRC, and GIST in the Netherlands. Detailed cost differences and value comparisons between these diagnostic techniques enable future economic evaluations to support decision-making.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available